M&T Bank Corp Revance Therapeutics, Inc. Transaction History

M&T Bank Corp

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 07, 2022	SELL	$12.46 - $27.87 $159,712 - $357,237	-12,818 Closed	0 $0
Q1 2021 May 06, 2021	BUY	$24.03 - $29.97 $36,333 - $45,314	1,512 Added 13.37%	12,818 $358,000
Q2 2020 Jul 29, 2020	BUY	$12.6 - $26.55 $617 - $1,300	49 Added 0.44%	11,306 $276,000
Q1 2020 May 14, 2020	SELL	$12.46 - $27.81 $31,611 - $70,553	-2,537 Reduced 18.39%	11,257 $167,000
Q3 2019 Nov 12, 2019	BUY	$10.22 - $14.5 $20,031 - $28,420	1,960 Added 16.56%	13,794 $179,000
Q2 2019 Aug 12, 2019	BUY	$10.67 - $15.49 $126,268 - $183,308	11,834 New	11,834 $153,000

234

82.8M

680K

896K

Ticker RVNC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 82,305,696
Market Cap $212M
Description
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...

Get notified when there are updates to the investment portfolio of M&T Bank Corp, based on Form 13F filings with the SEC.

Stay updated on M&T Bank Corp with notifications on news.